Lasix in Horse Racing: Science, Economics, and the 2026 HISA Turning Point

Last updated: April 1, 2026

By: Miles HenryFact Checked

By Miles Henry (William Bradley) | Louisiana Licensed Thoroughbred Owner #67012 | Fair Grounds & Delta Downs | Updated March 2026 | Equibase Stats

Lasix — the brand name for furosemide — is the most debated drug in American horse racing. It has been administered to racehorses before competition for decades, used primarily to control Exercise-Induced Pulmonary Hemorrhage (EIPH): the lung bleeding that affects an estimated 90% of Thoroughbreds under race conditions. It reduces that bleeding by 50–70%. It also causes horses to lose 20–30 pounds of fluid before the gate opens. That combination — legitimate medicine and measurable performance effect — is why no other medication in the sport generates the same argument.

I’ve owned racehorses in Louisiana for over 30 years, racing primarily at Fair Grounds and Delta Downs. I’ve scoped bleeders, managed horses on furosemide for entire careers, and watched the regulatory landscape shift from universal use to the fractured patchwork we operate under today. If you’re new to how racing works, the horse racing basics guide covers race types and structure before diving into medication policy. This article covers what Lasix actually does, why it remains controversial, how global rules compare, and what the HISA regulatory process means for owners, trainers, and bettors.

What Is Lasix and Why Do Racehorses Use It?

Lasix is the brand name for furosemide, a loop diuretic originally developed for human patients with congestive heart failure and kidney disease. In horses, it blocks sodium, potassium, and chloride reabsorption in the kidneys, dramatically increasing urine output and reducing total blood volume within hours of administration.

The connection to racing runs through pulmonary physiology. When a Thoroughbred races, its heart rate reaches 240 beats per minute and its spleen contracts to release up to 50% additional red blood cells into circulation — maximizing oxygen delivery to working muscles. That surge creates extreme pressure in the small capillaries of the lungs. In horses predisposed to EIPH, those capillaries rupture. The horse bleeds into its own lungs during the race. By reducing blood volume before the horse runs, furosemide lowers pulmonary capillary pressure and reduces the likelihood of rupture. Studies show it reduces pulmonary artery pressure by 10–15% (ACVIM Consensus Statement, JVIM).

The secondary effect — weight loss — is the contested part. A horse on Lasix loses 20–30 pounds of fluid before a race (Washington State University). Given that weight directly affects how hard a horse must work at race pace, that fluid loss is both a side effect of the treatment and a source of the performance enhancement argument. Whether it constitutes medicine, performance enhancement, or both is the core of thirty years of debate.

How Lasix Affects Racehorses: The Science Summary

Furosemide produces four measurable effects simultaneously. The benefits and risks operate in parallel, which is why managing a horse on Lasix requires attention to hydration, electrolytes, and recovery schedule — not just the pre-race injection. These effects also interact with the broader injury and conditioning picture for horses racing on tight schedules.

In practice, managing a horse on Lasix means limiting hay and water after the injection to prevent compounding the fluid loss, then monitoring electrolyte supplementation carefully in the days following each race. Trainers who skip that recovery protocol are the ones who see the drug’s negative effects accumulate across a meet.

The EIPH Debate: Medicine or Masking?

The ethical argument over Lasix has two legitimate positions. Neither is simply wrong, and understanding both matters whether you’re an owner, a bettor analyzing horses across class levels, or a fan following the regulatory story.

Supporters frame it as humane medicine. EIPH affects nearly every Thoroughbred at some level. Severe bleeding causes respiratory distress, impairs performance, and in extreme cases can be life-threatening. The ACVIM Consensus Statement — the most comprehensive veterinary review of the evidence — found furosemide effective in reducing EIPH incidence and severity, and recommended that EIPH be classified as a disease rather than a performance variable. If it’s a disease, the medication is treatment. More detail on EIPH severity grading and diagnosis is in the dedicated racehorse nosebleeds and EIPH guide.

Critics make two arguments. First, integrity: the weight loss effect is real and measurable, making furosemide a performance-enhancing drug regardless of its legitimate medical use. Second, genetic: by allowing horses with severe EIPH to compete successfully on medication, the industry reduces selection pressure against breeding bleeders — potentially worsening the condition across generations. This concern overlaps with broader questions about how injury and health predispositions are transmitted through Thoroughbred bloodlines.

Germany takes the most aggressive position — banning furosemide in both training and racing, and restricting confirmed bleeders from recognized breeding programs. The result over decades has been a lower incidence of severe EIPH in German Thoroughbred stock. The counterargument from American horsemen is that German racing structure — longer distances, grass-heavy, lower race frequency — creates a fundamentally different physiological environment than the claiming barn model in Louisiana or New York.

Lasix Rules by Country: Where It’s Banned, Restricted, and Allowed

The global picture on race-day furosemide is divided, and the United States has historically been the clear outlier in permissiveness. Understanding the international comparison requires context about each jurisdiction’s race structure and competition types — the policy environments aren’t directly equivalent.

The Kentucky Derby prohibited race-day Lasix starting in 2021. The Breeders’ Cup ran all 14 races Lasix-free the same year. Both experiments proceeded without the widespread breakdown concerns critics had raised. But stakes horses, managed at lower race frequencies with more resources, are a materially different population from the overnight claiming horses who account for the majority of starts at every American track.

Owner Economics: What Lasix Means in a Claiming Barn

The economic reality of Lasix in everyday racing rarely enters the policy debate, which tends to focus on elite horses and international prestige. The view from a Fair Grounds claiming barn is different in ways that matter to the sport’s operating economics.

A confirmed bleeder in the $10,000–$20,000 claiming range is a horse that needs to run every 25–35 days to justify its upkeep. Managed on furosemide, that horse can maintain a normal race schedule, compete at its natural class level, and generate the purse earnings and potential claiming transactions that make the barn financially viable. Without furosemide, the same horse needs longer recovery between starts, faces higher risk of visible bleeding episodes that affect its value and future entries, and may need to be retired earlier. The full picture of what racehorse ownership costs — and where EIPH management fits into that — is covered in the guide to the economics of owning racehorses.

The NYTHA survey published in BloodHorse in March 2026 quantified this directly: 81% of New York horsemen said they would race less if furosemide is banned in all races. A further 80% said they have already bypassed stakes races to keep horses eligible for Lasix in overnight conditions — a documented behavioral change under the current partial ban that is already reshaping how barns manage their condition book entries.

For bleeders in the two-year-old ranks — where HISA’s ban has already been in effect for two years — 47% of NYTHA members reported increased EIPH incidence and greater severity. Only 27% saw minimal or no change. The horses didn’t stop bleeding when the medication was removed. The management problem shifted from pharmaceutical to logistical.

Lasix Alternatives: Managing EIPH Without Furosemide

None of the available alternatives replicate furosemide’s primary mechanism — acutely reducing blood volume and pulmonary capillary pressure before a race. They address adjacent factors. In a well-resourced barn with time for a managed transition, some can meaningfully reduce EIPH severity. In a 20-horse claiming operation running horses every three weeks, the practical picture is more limited. A full review of EIPH management options is in the dedicated EIPH guide; here’s the summary relevant to the regulatory debate.

Equine nasal strips are the most studied non-pharmaceutical alternative. They support soft tissue in the nasal passages, reduce airway resistance, and lower pulmonary capillary pressure to a degree. They don’t cause weight loss, don’t carry electrolyte risks, and are permitted in all jurisdictions. In practice, they work best as a complement to other management — not a standalone replacement for a confirmed severe bleeder.

Selective breeding is the long-term structural answer. Germany’s model shows it works over decades. It doesn’t help a trainer managing this season’s condition book. If a horse is already a confirmed bleeder, genetics are a multi-generational solution, not a race-week one.

Training modification is the most actionable near-term option: longer recovery periods between races, graduated conditioning, and reduced race frequency can lower EIPH severity by reducing cumulative pulmonary stress. The WSU study currently analyzing 30,000 career records will provide data on whether career management changes can meaningfully offset furosemide removal. These training considerations also intersect with how injury prevention and conditioning are managed across a barn’s roster.

Dietary interventions — omega-3 fatty acids, antioxidants, anti-inflammatory protocols — are standard in well-managed barns regardless of Lasix status. They support lung health at the margins but have not been demonstrated to replicate furosemide’s acute pressure-reduction effect.

HISA and the Regulation of Lasix: A Timeline

American furosemide regulation has moved in one direction since 2020, with HISA incrementally narrowing where the drug is permitted. The May 2026 vote is the scheduled conclusion of a process that began when Congress passed the Horseracing Integrity and Safety Act — not a sudden shift.

Pre-HISA (before 2023): Furosemide was permitted in virtually all races across North America. Over 90% of North American racehorses ran on it. State racing commissions regulated individually with no federal uniformity.

2021: The Kentucky Derby and Breeders’ Cup voluntarily eliminated race-day Lasix, establishing that elite racing could function without it and creating political momentum for broader restrictions.

May 2023: HISA’s Anti-Doping and Medication Control program launched. Race-day furosemide was immediately banned in all two-year-old races and all stakes races. All other categories received a three-year exemption pending scientific review.

2024–2026: HISA funded three studies ($773,500 total across WSU, the University of Florida, and Nationwide Children’s Hospital) with final reports required by January 31, 2026. The Furosemide Advisory Committee reviews findings ahead of the board vote.

May 22, 2026: The HISA Board of Directors votes on whether to extend the exemption for overnight and claiming races. A unanimous yes preserves the current two-tier system. Any other outcome activates the statutory default: a full 48-hour pre-race ban across all race categories. Study summaries are posted at hisaus.org/admc/furosemide.

What the HISA Studies Are Examining

The three commissioned studies are the scientific foundation for the board’s decision. Their findings address the empirical questions the policy debate has circled for years without definitive data.

The University of Florida study (Dr. Sally Anne DeNotta) examines whether race-day furosemide is associated with fatal injuries, and compares career outcomes — length, starts per year, earnings, speed figures — between horses that raced as two-year-olds with Lasix and those that did not. This is the welfare-durability question: does furosemide extend careers or enable horses to race through conditions that shorten them?

The Nationwide Children’s Hospital study tracked repeated furosemide dosing effects on electrolyte homeostasis, parathyroid response, and urinary excretion in exercising Thoroughbreds. This addresses safety-of-use for horses racing every three to four weeks — the scenario directly relevant to the claiming barn model.

The WSU study (Dr. Warwick Bayly and Dr. Macarena Sanz) analyzed approximately 30,000 career records to determine whether furosemide correlates with more career starts and longer racing lives. The team’s stated hypothesis: horses receiving furosemide before racing have more career starts and longer careers than those that don’t. If confirmed, that framing reshapes the welfare argument — a ban would reduce career longevity, not protect it.

The central scientific tension is between EIPH management and cardiac-event prevention. HISA’s October 2025 statement emphasized Exercise-Associated Sudden Death linked to cardiac events. The National HBPA cited a University of Pennsylvania necropsy study in which nine of eleven sudden-death horses were attributable to EIPH — not cardiac causes — with no cardiac lesions found in any of the eleven. That tension between EIPH management and cardiac-event prevention is central to the board’s policy decision.

Post-Vote Scenarios: What Changes After May 22

The vote produces one of three outcomes, each with different implications for claiming barn operations, condition book economics, and handicapping angles.

Scenario A — Unanimous vote to preserve the partial exemption: Overnight and claiming races continue on furosemide. The two-tier system holds — stakes and 2YO banned, everything else still permitted — likely with new conditions and a defined timeline for further review. This is the outcome trainer organizations have publicly lobbied for, with trainers Mott, Brown, and Casse among the signatories to a February 2026 letter urging the board to follow the science rather than international precedent.

Scenario B — Statutory default activates: The 48-hour pre-race ban extends to all races. HISA has indicated a transition period before full enforcement. Many trainers anticipate fewer entries during the adjustment period, with the scale depending on how quickly alternative EIPH management can be adopted across barns at different resource levels.

Scenario C — Modified exemption: The board modifies current rules with new dosage restrictions, additional race categories banned, or a structured phase-out. Any modification requires unanimous agreement — politically difficult given the diverse constituencies across the nine-member panel.

First Lasix Handicapping: Betting Angles That Work in Any Regulatory Environment

The Lasix designation in the program is one of the most consistently actionable signals in handicapping — and it functions regardless of which direction the May 22 vote goes, because the program will always tell you when a horse’s furosemide status has changed. These angles slot naturally into the broader four-point readiness filter for identifying horses pointed to win. For bettors newer to the mechanics of how to structure the actual wager, the complete betting guide covers bet types and strategy before applying drug-signal angles.

First-time Lasix is the strongest positive signal in claiming and allowance races. When a trainer puts a horse on furosemide for the first time, the most common explanations are: a scope confirmed bleeding after a pattern of front-running-and-fading; the horse is dropping from stakes company (where Lasix is already banned) to claiming where it’s still permitted; or the horse has consistently underperformed its works and the barn suspects EIPH. All three scenarios historically produce genuine performance improvement that the past performances don’t explain.

Stakes to claiming, off Lasix to on Lasix is the most valuable new angle created by HISA’s two-tier rules. A horse with an EIPH history that has been running in stakes company drops to overnight claiming for its first Lasix-eligible start. The crowd reads the flat stakes form and discounts the drop; the Lasix addition is the variable they’re missing. That informational gap is where value lives.

Repeat Lasix on a peaked form cycle is the fading angle. A horse that ran its career best three starts ago, declining since, returning at the same level with the same medication and no changes — that’s a barn finding a spot, not one pointing to win. I pass those regardless of the morning line.

Off Lasix voluntarily mid-career (not forced by stakes eligibility) is worth flagging. A trainer removing furosemide from a chronic claimer without a class change as the explanation often signals the medication isn’t producing the expected effect — which can mean the EIPH is more severe than anticipated, or form is declining for reasons beyond what Lasix manages.

Lasix Handicapping Filter: $16K Fair Grounds Claimer

This table applies the angles above to a representative Fair Grounds $16,000 claiming race. The profiles are drawn from real barn patterns at this level. For the full handicapping framework these Lasix signals fit within — including fitness, form cycle, trainer intent, and class — see the 4-point filter guide. For bet structuring across these signals, see the guide to horse racing bet types.

Scroll right to view full table on mobile

Teaching example based on typical Fair Grounds $16k claiming profiles. Not a specific race. Always verify program Lasix designations on race day.

Frequently Asked Questions: Lasix in Horse Racing

Miles Henry

About Miles Henry

Racehorse Owner & Author | 30+ Years in Thoroughbred Racing

Miles Henry (legal name: William Bradley) is a professional horseman based in Folsom, Louisiana. He holds Louisiana Racing License #67012 and has spent over three decades managing Thoroughbreds at premier tracks including Fair Grounds, Delta Downs, and Evangeline Downs.
Expertise & Hands-On Experience: Beyond the track, Miles has decades of experience in specialized equine care, covering everything from hoof health and nutrition to training protocols for Quarter Horses, Friesians, and Paints. Every guide on Horse Racing Sense is rooted in this “boots-on-the-ground” perspective.
30 of their last 90 starts
Equibase Profile.

Connect with Miles:

• Live Stats
• Books
• Newsletter
• Twitter
• Facebook